Understanding the Role of Finerenone Among Current Treatment Options for Diabetic Kidney Disease

Abstract

Get full access to this article

View all access options for this article.

References

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115.

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.

Agarwal

Filippatos

Pitt

, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484.

American Diabetes Association. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(suppl 1):S244-S253.

Bakris

Agarwal

Anker

, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.

de Boer

Khunti

Sadusky

, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090.

Green

Mottl

Bakris

, et al. Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2022;gfac198.

Kerendia. Package insert. Bayer HealthCare Pharmaceuticals Inc; 2021.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;3(1):S1-S150.

10.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127.

11.

Palanisamy

Hernandez

Chang

Mahaffey

Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist. Cardio Ther. 2022;11:337-354.

12.

Pitt

Filippatos

Agarwal

, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263.